ConductScience.org, home

Paper37736699

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.

Xia Z and 8 others. Infect Dis Poverty, 2023. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Papers, record 37736699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37736699

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
PubMed
Journal
Infect Dis Poverty
PubMed
Year
2023
PubMed
Publication types
Meta-Analysis, Systematic Review, Journal Article
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
2.86
iCite
Revised in PubMed
2025-06-26
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xia ZZhengzheng
2Zhang JJianyu
3Chen WWenjun
4Zhou HHaiyan
5Du DDi
6Zhu KKongcai
7Chen HHui
8Meng JJun
9Yang JJun

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Hepatitis BMajor topic
Humans
Immune Checkpoint Inhibitors
Retrospective Studies
Hepatitis B virus

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
320.6750.2022.20-24Wu Jieping Medical FoundationPubMed
NCC201919B03National Cancer Center Pandeng FoundationPubMed

Source PubMed

Download CSV of grants

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136221140Impact of the national hepatitis B immunization program in China: a modeling study.Infect Dis Poverty2022https://conductscience.org/library/papers/36221140PubMed
235297794Comparative Safety, Efficacy and Survival Outcome of Anti-PD-1 Immunotherapy in Colorectal Cancer Patients With vs Without Hepatitis B Virus Infection: A Multicenter Cohort Study.Clin Transl Gastroenterol2022https://conductscience.org/library/papers/35297794PubMed
335421228Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.Clin Cancer Res2022https://conductscience.org/library/papers/35421228PubMed
433139266Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.Clin Cancer Res2021https://conductscience.org/library/papers/33139266PubMed
534371536[Effects of programmed death receptor-1 antibody in patients with hepatitis B-associated liver cancer].Zhonghua Gan Zang Bing Za Zhi2021https://conductscience.org/library/papers/34371536PubMed
628241095Immune checkpoint inhibitors in challenging populations.Cancer2017https://conductscience.org/library/papers/28241095PubMed
735601125Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.JGH Open2022https://conductscience.org/library/papers/35601125PubMed
835611266
Updated Survival and Secondary Safety and Efficacy Analyses From CA 209-678: A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y)2021https://conductscience.org/library/papers/35611266PubMed
936580258Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.Hepatol Int2023https://conductscience.org/library/papers/36580258PubMed
1032423643Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.Lung Cancer2020https://conductscience.org/library/papers/32423643PubMed
1134430357Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy.Transl Lung Cancer Res2021https://conductscience.org/library/papers/34430357PubMed
1236589726Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).Liver Cancer2022https://conductscience.org/library/papers/36589726PubMed
132230000Spontaneous reactivation in chronic hepatitis B: patterns and natural history.J Clin Gastroenterol1990https://conductscience.org/library/papers/2230000PubMed
1433241036Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.Ann Transl Med2020https://conductscience.org/library/papers/33241036PubMed
1533560651Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection.Am J Gastroenterol2021https://conductscience.org/library/papers/33560651PubMed
1634918361Risk of HBV reactivation during therapies for HCC: A systematic review.Hepatology2022https://conductscience.org/library/papers/34918361PubMed
1731753012Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.J Immunother Cancer2019https://conductscience.org/library/papers/31753012PubMed
1819621070The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.PLoS Med2009https://conductscience.org/library/papers/19621070PubMed
1928434648Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017https://conductscience.org/library/papers/28434648PubMed
2029875066Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol2018https://conductscience.org/library/papers/29875066PubMed

See all 56 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
42829048Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach.Virus Res2026https://conductscience.org/library/papers/42829048PubMed
42792706Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach.Biomedicines2026https://conductscience.org/library/papers/42792706PubMed
42757131Regulatory T-cell remodeling across the HBV infection-cirrhosis continuum.Front Immunol2026https://conductscience.org/library/papers/42757131PubMed
42614304Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.Front Immunol2026https://conductscience.org/library/papers/42614304PubMed
42233029Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease.Front Immunol2026https://conductscience.org/library/papers/42233029PubMed
42176073Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42176073PubMed
42125666Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Front Immunol2026https://conductscience.org/library/papers/42125666PubMed
42112392Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.Front Immunol2026https://conductscience.org/library/papers/42112392PubMed
41898402Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.Int J Mol Sci2026https://conductscience.org/library/papers/41898402PubMed
41784912Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clin Exp Med2026https://conductscience.org/library/papers/41784912PubMed
41743730HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Front Immunol2026https://conductscience.org/library/papers/41743730PubMed
41566859Letter: Using Anti-HBs Titers to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours-Authors' Reply.Aliment Pharmacol Ther2026https://conductscience.org/library/papers/41566859PubMed
41479885Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats.Front Immunol2025https://conductscience.org/library/papers/41479885PubMed
41183666Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms.Virus Res2025https://conductscience.org/library/papers/41183666PubMed
41152543The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clin Exp Med2025https://conductscience.org/library/papers/41152543PubMed
40762016Neoadjuvant immunotherapy for resectable primary liver cancer (Review).Oncol Lett2025https://conductscience.org/library/papers/40762016PubMed
40426198Nanoparticle-mediated SIRT1 inhibition suppresses M2 macrophage polarization and hepatocarcinogenesis in chronic hepatitis B.J Nanobiotechnology2025https://conductscience.org/library/papers/40426198PubMed
40301863Clinical correlation and survival analysis of hepatitis B virus infection in oral squamous cell carcinoma: a retrospective study of 1373 patients.BMC Cancer2025https://conductscience.org/library/papers/40301863PubMed
40160817The role of immune regulation in HBV infection and hepatocellular carcinogenesis.Front Immunol2025https://conductscience.org/library/papers/40160817PubMed
39796705Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.Cancers (Basel)2024https://conductscience.org/library/papers/39796705PubMed

See all 28 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37736699

GET https://conductscience.org/api/papers/v1/37736699/references?page=2